Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.   Report issue

For profit Phase 3
Founded: Changzhou China (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2013
NCT02070523
First Marketed Drug
2016
rosuvastatin (crestor)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CHANGZHOU PHARM

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 5